This Phase 2 study aims to study to evaluate the efficacy and safety of study treatment in paticipants with Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease Dementia
Age 50 - 80
Mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease
The primary objective of this study is to verify the clinical benefit of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score as compared with placebo in participants with early Alzheimer's disease.
Age 60 - 85
Must have a study partner
This is a phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study that will assess efficacy and safety of AL002 administered intravenously (IV) in participants with Early Alzheimer's Disease.